Fibrosis and anti-TNF is under clinical development by 180 Life Sciences and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Fibrosis and anti-TNF’s likelihood of approval (LoA) and phase transition for Dupuytren Contracture took place on 21 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Fibrosis and anti-TNF Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Fibrosis and anti-TNF overview
Anti-TNF monoclonal antibody is under development for the treatment of Dupuytren's contracture, Post operative cognitive dementia (POCD), non-alcoholic steatohepatitis (NASH) and frozen shoulder syndrome. The drug candidate is administered through subcutaneous and intraarticular route.. It targets the tumor necrosis factor alpha. The drug candidate was also under development for the treatment of periarticular disease . It is a repurposed drug of adalimumab.
180 Life Sciences overview
180 Life Sciences is developing new treatments for one of the world’s biggest drivers of disease. The company is headquartered in the US.
Quick View Fibrosis and anti-TNF LOA Data
|Highest Development Stage|